CL2017001040A1 - Methods to treat filoviridae virus infections - Google Patents

Methods to treat filoviridae virus infections

Info

Publication number
CL2017001040A1
CL2017001040A1 CL2017001040A CL2017001040A CL2017001040A1 CL 2017001040 A1 CL2017001040 A1 CL 2017001040A1 CL 2017001040 A CL2017001040 A CL 2017001040A CL 2017001040 A CL2017001040 A CL 2017001040A CL 2017001040 A1 CL2017001040 A1 CL 2017001040A1
Authority
CL
Chile
Prior art keywords
methods
treat
virus
virus infections
filoviridae virus
Prior art date
Application number
CL2017001040A
Other languages
Spanish (es)
Inventor
Byoung Kwon Chun
Michael Oneil Hanrahan Clarke
Edward Doerffler
Hon Chung Hui
Robert Jordan
Richard L Mackman
Jay P Parrish
Adrian S Ray
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54557474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2017001040A1 publication Critical patent/CL2017001040A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>SE PROPORCIONAN COMPUESTOS, MÉTODOS, Y COMPOSICIONES FARMACÉUTICAS PARA TRATAR INFECCIONES POR EL VIRUS FILOVIRIDAE ADMINISTRANDO RIBÓSIDOS, FOSFATOS DE RIBÓSIDO, Y PROFÁRMACOS DEL MISMO, DE FÓRMULA IV LOS COMPUESTOS, COMPOSICIONES, Y MÉTODOS PROVISTOS SON PARTICULARMENTE ÚTILES PARA EL TRATAMIENTO DE INFECCIONES POR EL VIRUS DE MARBURG, VIRUS DE EBOLA Y VIRUS CUEVA.</p><p> PHARMACEUTICAL COMPOUNDS, METHODS, AND COMPOSITIONS ARE PROVIDED TO TREAT INFECTIONS BY THE VIRUS FILOVIRIDAE MANAGING RIBOSIDS, RIBOSIDE PHOSPHATES, AND PROMISES OF THE SAME, COMPOSITION MATERIALS, AND COMPOSITION PROVES FOR THE MARBURG VIRUS, EBOLA VIRUS AND CAVE VIRUS. </p>

CL2017001040A 2014-10-29 2017-04-26 Methods to treat filoviridae virus infections CL2017001040A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462072331P 2014-10-29 2014-10-29
US201562105619P 2015-01-20 2015-01-20

Publications (1)

Publication Number Publication Date
CL2017001040A1 true CL2017001040A1 (en) 2018-01-19

Family

ID=54557474

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017001040A CL2017001040A1 (en) 2014-10-29 2017-04-26 Methods to treat filoviridae virus infections
CL2017002693A CL2017002693A1 (en) 2014-10-29 2017-10-24 Methods to treat filoviridae virus infections. divisional application n ° 1040-2017.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017002693A CL2017002693A1 (en) 2014-10-29 2017-10-24 Methods to treat filoviridae virus infections. divisional application n ° 1040-2017.

Country Status (45)

Country Link
US (8) US9724360B2 (en)
EP (7) EP3366295B1 (en)
JP (9) JP6220484B1 (en)
KR (6) KR102337664B1 (en)
CN (6) CN113549120B (en)
AR (2) AR102468A1 (en)
AU (8) AU2015339223B2 (en)
BR (2) BR102015027413A2 (en)
CA (4) CA2963832C (en)
CL (2) CL2017001040A1 (en)
CO (1) CO2017003960A2 (en)
CR (2) CR20170165A (en)
CU (2) CU20170145A7 (en)
CY (2) CY1120893T1 (en)
DK (2) DK3212174T3 (en)
DO (1) DOP2017000103A (en)
EA (2) EA032239B1 (en)
EC (2) ECSP17025261A (en)
ES (5) ES3020561T3 (en)
HR (1) HRP20181130T1 (en)
HU (2) HUE049192T2 (en)
IL (2) IL251560A0 (en)
LT (2) LT3366295T (en)
MA (3) MA52506A (en)
MD (1) MD20170046A2 (en)
ME (1) ME03070B (en)
MX (3) MX378299B (en)
MY (1) MY195823A (en)
NZ (3) NZ745328A (en)
PE (2) PE20171439A1 (en)
PH (2) PH12017500631B1 (en)
PL (5) PL3212175T3 (en)
PT (4) PT3695844T (en)
RS (1) RS57425B1 (en)
SA (1) SA517381419B1 (en)
SG (3) SG11201702903TA (en)
SI (4) SI3366295T1 (en)
SM (1) SMT201800381T1 (en)
SV (2) SV2017005424A (en)
TR (1) TR201809518T4 (en)
TW (4) TWI698444B (en)
UA (1) UA121485C2 (en)
UY (2) UY36376A (en)
WO (3) WO2016069825A1 (en)
ZA (1) ZA201800414B (en)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599404A (en) 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
PT2595980E (en) 2010-07-22 2014-11-27 Gilead Sciences Inc METHODS AND COMPOUNDS FOR TREATING INFECTIONS BY THE PARAMYXOVIRIDAE FAMILY VIRUS
TWI698444B (en) 2014-10-29 2020-07-11 美商基利科學股份有限公司 Methods for the preparation of ribosides
DK3349758T3 (en) 2015-09-16 2022-06-13 Gilead Sciences Inc PROCEDURES FOR THE TREATMENT OF ARENAVIRIDAE VIRUS INFECTIONS
WO2018089306A1 (en) * 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
CA3043437A1 (en) * 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Liver prodrugs of mitochondrial proton ionophores
CN110869028B (en) 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
JP6923112B2 (en) * 2017-03-31 2021-08-18 国立大学法人北海道大学 Biarylsulfonamide derivative with filovirus cell invasion inhibitory activity
EP4219513A1 (en) * 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (en) 2017-07-11 2024-03-08 吉利德科学公司 Compositions containing RNA polymerase inhibitors and cyclodextrins for treating viral infections
WO2019053696A1 (en) 2017-09-18 2019-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109535200A (en) * 2017-09-21 2019-03-29 杭州和正医药有限公司 A kind of phosphoramidate prodrug, pharmaceutical composition and its application of nucleoside analog
CN109748943A (en) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 2 '-C- methyl substituted nucleosides class compounds and its preparation and purposes
CN109748944B (en) * 2017-11-03 2021-12-10 中国科学院上海药物研究所 5 '-deoxy-5' -isopropyl substituted amino nucleoside compound, and preparation method and application thereof
CN110330540A (en) * 2019-08-08 2019-10-15 木天(济南)生物科技有限公司 Nucleosides salt and preparation method thereof
CN110613726B (en) * 2019-09-25 2020-10-16 广州六顺生物科技股份有限公司 Applications of Nucleoside Compounds
WO2021095091A1 (en) * 2019-11-11 2021-05-20 藤本化学製品株式会社 Aminoaryl derivative, intermediate of same, method for producing said aminoaryl derivative, and method for producing said intermediate
CN110776512A (en) * 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 Preparation method of nucleoside analogue
KR20220132608A (en) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 Methods for treating SARS CoV-2 infection
WO2021158248A1 (en) 2020-02-04 2021-08-12 Oyagen, Inc. Method for treating coronavirus infections
CN113214263B (en) * 2020-02-06 2022-09-30 北京桦冠医药科技有限公司 Synthetic method of Rudesiwei key intermediate
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN111205327B (en) * 2020-02-17 2022-05-31 南京法恩化学有限公司 Preparation method of Reideciclovir
TWI791193B (en) * 2020-02-18 2023-02-01 美商基利科學股份有限公司 Antiviral compounds
TWI794742B (en) 2020-02-18 2023-03-01 美商基利科學股份有限公司 Antiviral compounds
KR20250133471A (en) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 Antiviral compounds
TWI775313B (en) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 Antiviral compounds
CN113292565B (en) * 2020-02-24 2023-01-31 浙江森科建设有限公司 Nucleoside compound and preparation method and application thereof
CN111205294B (en) * 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 A kind of preparation method of Remdesivir intermediate
CN111187269A (en) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 Synthetic method of Reidesciclovir intermediate
CN111171078B (en) * 2020-02-27 2022-04-22 江苏阿尔法药业股份有限公司 A kind of synthetic method of Remdesivir
WO2021175296A1 (en) * 2020-03-04 2021-09-10 中国科学院上海药物研究所 Intermediate of remdesivir and preparation method therefor
CN111233930B (en) * 2020-03-04 2022-05-13 江苏阿尔法药业股份有限公司 Preparation method of Reidesciclovir
CN111269248A (en) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 A new method for recovery of nucleoside phosphoramidate drug mother liquor
CN111269263A (en) * 2020-03-09 2020-06-12 上海龙翔生物医药开发有限公司 Rudexilvir side chain intermediate and preparation method thereof
CN113387954B (en) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 A kind of preparation method of remdesivir intermediate
CN111233870A (en) * 2020-03-11 2020-06-05 中国科学技术大学 Method for rapidly preparing remdesivir pharmaceutical intermediates
TWI785528B (en) * 2020-03-12 2022-12-01 美商基利科學股份有限公司 Methods of preparing 1’-cyano nucleosides
CN111233869B (en) * 2020-03-12 2022-09-16 杭州新博思生物医药有限公司 Novel compound for preparing Rudexilvir key intermediate and preparation method thereof
CN113402546A (en) * 2020-03-17 2021-09-17 浙江四维医药科技有限公司 Dynamic kinetic resolution method for tail chain of Rudesiwei phosphate intermediate
EP4107186A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
JP2023518814A (en) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Biomarkers for predicting response to IL-6 antagonists in COVID-19 pneumonia
CN111233931B (en) * 2020-03-26 2022-03-22 宿迁盛基医药科技有限公司 Synthesis method of Reidesciclovir
CN111398464B (en) * 2020-04-02 2022-03-08 广州隽沐生物科技股份有限公司 Method for detecting 2-ethylbutyl ((perfluorophenoxy) (phenoxy) phosphoryl) -L-alanine ester
CN111423443A (en) * 2020-04-03 2020-07-17 广州科锐特生物科技有限公司 A kind of preparation method of 4-amino-7-iodopyrrolo[2,1-f][1,2,4]triazine
CN113493480B (en) * 2020-04-03 2025-04-15 南京正大天晴制药有限公司 A preparation method of a remdesivir isomer and its analysis method
JP7482250B2 (en) * 2020-04-06 2024-05-13 ギリアード サイエンシーズ， インコーポレイテッド Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
US12472197B2 (en) 2020-04-07 2025-11-18 Island Pharmaceuticals, Ltd. Methods, compositions, and dosing regimens for treatment of SARS-CoV-2 infections
WO2021208910A1 (en) * 2020-04-13 2021-10-21 山东华铂凯盛生物科技有限公司 Polymer preparation for treating virus infection, and preparation method therefor and use thereof
CN111393494A (en) * 2020-04-17 2020-07-10 广东帕派恩生物科技有限公司 Compound based on nucleotide structure, preparation method and application
CN112778310B (en) 2020-04-20 2025-05-30 中国科学院上海药物研究所 Application of nucleoside analogs or combination preparations containing nucleoside analogs in antiviral treatment
EP4143199B1 (en) * 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
CN111471070B (en) * 2020-04-26 2022-05-13 江苏阿尔法药业股份有限公司 Synthetic method of Remdesivir
CN111454270B (en) * 2020-04-27 2024-05-14 南通伟顺生物科技有限公司 Nucleoside compound containing six-membered ring and preparation method thereof
CN111440176B (en) * 2020-04-28 2022-04-26 江苏大学 Metal complex promoted synthesis method of Reidesciclovir intermediate
US10988503B1 (en) * 2020-05-06 2021-04-27 Nantong Weishun Biotechnology Co., Ltd Six-membered ring-containing nucleoside compound and preparation method thereof
CN113637041B (en) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 Preparation method of ribonucleoside
WO2021234554A2 (en) * 2020-05-20 2021-11-25 Lyrus Life Sciences Pvt Ltd Novel composition for the treatment of viral infections
RU2740660C1 (en) * 2020-05-20 2021-01-19 Общество С Ограниченной Ответственностью "Промомед Рус" Antiviral composition
WO2021237109A1 (en) 2020-05-22 2021-11-25 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN111961057A (en) * 2020-05-26 2020-11-20 李小冬 Alpha-configuration nucleoside and application thereof in treating feline coronavirus infection
EP4157272B1 (en) 2020-05-29 2025-07-02 Gilead Sciences, Inc. Remdesivir for the treatment of viral infections
EP3915548A1 (en) 2020-05-29 2021-12-01 Jubilant Generics Limited Transmucosal pharmaceutical compositions of antiviral drugs
IN202011022634A (en) 2020-05-29 2020-10-09 Jubilant Generics Limited
CN113754694B (en) * 2020-06-03 2022-10-25 上海交通大学 Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside
CN113754693B (en) * 2020-06-03 2022-09-09 上海交通大学 Asymmetric catalytic synthesis method and catalyst of phosphochiral nucleoside derivatives
CN113754692B (en) * 2020-06-03 2022-06-10 上海交通大学 Asymmetric catalytic synthesis of remdesivir intermediate (S,S)-phosphoramidate
WO2021257569A1 (en) 2020-06-15 2021-12-23 Metro International Biotech, Llc Anti-viral compounds and methods of use
CN111620903A (en) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-nucleoside analogue, preparation method and application of nitrile-containing C-nucleoside compound for synthesizing Rudexilvir
WO2021262715A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation
IL299202A (en) 2020-06-24 2023-02-01 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
CN111732618A (en) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) Synthesis method of key fragments of Remdesivir
CN111961079A (en) * 2020-07-17 2020-11-20 南京正济医药研究有限公司 Ruideciclovir related substance and preparation method and application thereof
MX2023001002A (en) * 2020-07-24 2023-03-01 Univ California Antiviral prodrugs, pharmaceutical formulations, and methods.
LT4192839T (en) 2020-08-06 2025-11-25 REMDESIVIR INTERMEDIATES
CN113004330A (en) * 2020-08-22 2021-06-22 齐鲁制药有限公司 Preparation method of high-purity Reidesvir
JP7559223B2 (en) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド Phospholipid compounds and uses thereof
US11926645B2 (en) * 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN114105989A (en) * 2020-08-31 2022-03-01 中国科学院大连化学物理研究所 Preparation method and application of iodo-pyrrolotriazine amine compound
WO2022060412A1 (en) 2020-09-17 2022-03-24 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
CN112321642A (en) * 2020-09-28 2021-02-05 南京正济医药研究有限公司 Ruidexiwei related substance and preparation method and application thereof
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
CN112194661B (en) * 2020-10-22 2021-06-08 威海同丰海洋生物科技有限公司 Preparation method of 4-amino-7-iodopyrrolo [2, l-f ] [ l,2,4] triazine
JP7711900B2 (en) * 2020-10-26 2025-07-23 蘇州旺山旺水生物医薬股▲ふん▼有限公司 Nucleoside analogue salts and their crystalline forms, pharmaceutical compositions and uses
CN114456212A (en) * 2020-11-09 2022-05-10 广东东阳光药业有限公司 Preparation method of phosphorus-containing compound
CN114507256B (en) * 2020-11-16 2025-02-28 上海医药集团股份有限公司 A chiral isomer of remdesivir, preparation method and application thereof
RU2756921C1 (en) * 2020-11-20 2021-10-07 Общество С Ограниченной Ответственностью "Технология Лекарств" Method for obtaining remdesivir and phosphoramidates
CA3200885A1 (en) 2020-11-23 2022-05-27 Genentech, Inc. Methods for modulating host cell surface interactions with sars-cov-2
CN112358513A (en) * 2020-12-02 2021-02-12 上海朴颐化学科技有限公司 Method for preparing Reidesciclovir intermediate by using continuous flow reactor
CN114621229B (en) * 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 Compounds or compositions for treating or preventing infectious peritonitis in cats
CN114644666B (en) * 2020-12-18 2026-03-03 上海特化医药科技有限公司 Process for the preparation of 5' -nucleoside prodrugs and intermediates
CN114685511A (en) * 2020-12-25 2022-07-01 上海科胜药物研发有限公司 Purification method of Reidesciclovir intermediate
CN114685558A (en) * 2020-12-28 2022-07-01 尚科生物医药（上海）有限公司 Preparation method of Reidesciclovir intermediate
CN113754665B (en) * 2020-12-30 2022-08-19 南方科技大学 Preparation method of nucleoside compound
CN116370479B (en) * 2020-12-30 2024-02-13 南方科技大学 Use of compound ATV014 in the preparation of a product for the treatment of novel coronavirus infection
US12558364B2 (en) 2021-01-20 2026-02-24 Regents Of The University Of Minnesota Next generation remdesivir antivirals
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2022166581A1 (en) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 Nucleotide derivative, pharmaceutical composite thereof and use thereof
CN117157081A (en) * 2021-02-19 2023-12-01 南京赛弗斯医药科技有限公司 Nucleotide derivative with anti-tumor activity, and pharmaceutical composition and application thereof
CN112979736B (en) * 2021-03-04 2022-03-25 南京欧信医药技术有限公司 Preparation method of Reidesciclovir
CN115109077A (en) * 2021-03-18 2022-09-27 上海医药集团股份有限公司 Preparation method of Reidesciclovir intermediate
TWI845919B (en) 2021-04-16 2024-06-21 美商基利科學股份有限公司 Methods of preparing carbanucleosides using amides
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US12427150B2 (en) 2021-05-26 2025-09-30 Gilead Sciences, Inc. Phospholipid formulations of 1′-cyano substituted carba-nucleoside analogs
CN113683640B (en) * 2021-08-10 2025-01-14 浙江华海药业股份有限公司 A preparation method of butyl remdesivir
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
CN113999237B (en) * 2021-10-29 2023-08-08 润佳（苏州）医药科技有限公司 A kind of nucleoside prodrug and its application
KR102675967B1 (en) 2021-11-02 2024-06-17 충남대학교산학협력단 Nanostructured lipid carriers containing remdesivir, preparation method thereof, and pharmaceutical composition comprising the same
JP2025508656A (en) 2022-01-26 2025-04-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Antiviral prodrugs, intermediate and long acting formulations, and methods
CN114409655A (en) * 2022-01-26 2022-04-29 郑州大学 3',4'-Unsaturated ribose C-nucleoside analog and preparation method thereof
KR20240154647A (en) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 Compounds and methods for treating viral infections
CN115028672A (en) * 2022-06-14 2022-09-09 南京正济医药研究有限公司 Remdesivir intermediate crystal and preparation method thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
CN116874491B (en) * 2022-07-12 2026-05-26 深圳安泰维生物医药有限公司 An N-protected pyrrolotriazine C-glycoside compound and its preparation method
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
JP2025540572A (en) 2022-11-18 2025-12-16 ギリアード サイエンシーズ， インコーポレイテッド How to Treat a Poxvirus Infection
CN115737675B (en) * 2022-11-28 2024-03-08 安徽农业大学 Preparation of oxidized sodium selenosulfate and its application in the treatment of coronavirus infection
CN115947759A (en) * 2022-12-13 2023-04-11 安徽大学 A preparation method for treating new crown drug remdesivir
CN116332996B (en) * 2023-05-04 2025-04-01 南京颐媛生物医学研究院有限公司 L-ribofuranose anti-coronavirus compound and preparation method and application thereof
CN116284135B (en) * 2023-05-04 2025-03-21 南京颐媛生物医学研究院有限公司 Preparation method and application of anti-coronavirus nucleoside compounds
HUP2300153A1 (en) 2023-05-09 2024-11-28 Rotachrom Tech Zrt Process for separation of phosphor stereoisomers of remdesivir via achiral liquid-liquid chromatography
CN116554176A (en) * 2023-05-11 2023-08-08 南京正济医药研究有限公司 A kind of preparation method of nucleoside compound
CN117126199B (en) * 2023-05-17 2024-12-06 江西师范大学 A method for synthesizing fluororemdesivir
CN117343114B (en) * 2023-09-22 2026-05-19 山东大学 A method for constructing α-xylopyranoside bonds with high stereoselectivity
KR20260079626A (en) 2023-09-28 2026-06-02 길리애드 사이언시즈, 인코포레이티드 Compounds and methods for treating viral infections
CN117800872A (en) * 2023-12-25 2024-04-02 海门瑞一医药科技有限公司 A kind of synthesis method of 4-hydroxybutyronitrile

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ES2083580T3 (en) 1990-06-13 1996-04-16 Arnold Glazier PHOSPHORIC DRUGS.
DK0481214T3 (en) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prophylactic drugs of phosphonates
JPH1017629A (en) 1996-07-04 1998-01-20 Kayaku Akzo Kk Hard-coating resin composition and method for curing the same
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
KR20010041533A (en) 1998-03-03 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 New salt forms of (2e)-5-amino-5-methylhex-2-enoic acid n-methyl-n-((1r)-1-(n-methyl-n-((1r)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphtyl)ethyl)amide
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6475985B1 (en) 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
DE69936998T2 (en) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon PYRAZOLOTRIAZINE DERIVATIVES AS GABA RECEPTOR LIGANDS
DE19912636A1 (en) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents
IL145496A0 (en) * 1999-03-24 2002-06-30 Exiqon As Improved synthesis of [2.2.1] bicyclo nucleosides
WO2000075157A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Oligonucleotide synthesis with lewis acids as activators
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001019375A1 (en) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
SK11922002A3 (en) 2000-02-18 2003-06-03 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
HRP20030047B1 (en) 2000-07-21 2016-02-26 Gilead Sciences, Inc. MEDICINES THAT ARE PHOSPHONATE ANALYSIS OF NUCLEOTIDS AND THE METHODS OF SELECTION AND PREPARATION thereof
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR20090089922A (en) 2000-10-18 2009-08-24 파마셋 인코포레이티드 Modified nucleosides for the treatment of viral infections and abnormal cell proliferation
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
MXPA03006514A (en) 2001-01-22 2004-12-02 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase.
DE10145223A1 (en) 2001-09-13 2003-04-03 Basf Ag Process for the preparation of meso-zeaxanthin
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (en) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh PROCESS FOR THE PREPARATION OF PROTECTED, ENANTIOMERIC ENRICHED CYANHYDRINES BY IN SITU DERIVATIZATION
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
RU2004128943A (en) 2002-02-28 2005-04-20 Байота, Инк. (Us) MEDICINES SIMULATING NUCLEOTIDES AND THEIR MEDICINAL FORMS
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
BR0309581A (en) 2002-05-06 2005-03-29 Genelabs Tech Inc Nucleoside derivatives for treatment of hepatitis c virus infection
AU2003233667A1 (en) 2002-05-23 2003-12-12 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
EP1646371A4 (en) 2003-06-26 2010-09-22 Biotron Ltd Antiviral compounds and methods
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ATE478886T1 (en) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc PURINE NUCLEOSIDES FOR THE TREATMENT OF DISEASES CAUSED BY FLAVIVIDRAE, INCLUDING HEPATITIS C
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
JP2005185235A (en) * 2003-12-26 2005-07-14 Univ Of Tokyo Methods and kits for diagnosis of susceptibility to viral infection.
JP2005187428A (en) * 2003-12-26 2005-07-14 Univ Of Tokyo Anti-MGL antibody treatment for filovirus
EA011158B1 (en) 2004-03-16 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх GLUCOPIRANOZE-SUBSTITUTED BENZENE DERIVATIVES CONTAINING THESE COMPOUNDS MEDICINES, THEIR APPLICATION AND METHOD FOR THEIR PRODUCTION
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
ES2725457T3 (en) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparation of ribofuranosyl pyrimidines and 2'fluoro-2'-alkyl-substituted or other optionally substituted purines and their derivatives
CN101043893A (en) 2004-10-21 2007-09-26 默克公司 Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
AU2005317081A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
JP2008524162A (en) 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Glucopyranosyl-substituted benzene derivative, drug containing the compound, use thereof and production method thereof
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
CA2602533A1 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Use of c-nucleoside analogs for treatment of hepatitis c related viral infections
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8669280B2 (en) 2005-06-24 2014-03-11 Biotron Limited Antiviral compounds and methods
ES2436404T3 (en) 2005-10-03 2013-12-30 University Health Network ODCase inhibitors for the treatment of malaria
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
SI1954264T1 (en) 2005-12-01 2010-01-29 Basilea Pharmaceutica Ag PROCEDURE FOR PREPARATION OF EPOXYBUTANOL INTERMEDIATES
PE20070855A1 (en) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
BRPI0619146A2 (en) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp Substituted 4-amino-pyrroltriazine derivatives useful in the treatment of disorders and hyperproliferative diseases associated with angiogenesis
JP5112328B2 (en) 2005-12-09 2013-01-09 バジリア ファルマスーチカ アーゲー 4-Oxo (iso) tretinoin for topical treatment of severe dermatological disorders
BRPI0619563A2 (en) 2005-12-09 2011-10-04 Pharmasset Inc antiviral nucleosides
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (en) * 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Process for the synthesis of organoelement compounds
CL2007001427A1 (en) 2006-05-22 2008-05-16 Novartis Ag 5-AMINO-3- MALEATE SALT (2 ', 3'-DI-O-ACETYL-BETA-D-RIBOFURANOSIL) -3H-TIAZOLO [4,5-D] PIRIMIDIN-2-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF A PO INFECTION
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
AR063569A1 (en) * 2006-11-06 2009-02-04 Boehringer Ingelheim Int DERIVATIVES OF BENZIL- BENZONITRILE SUBSTITUTED WITH GLUCOPYRANOSIL MEDICINES CONTAINING COMPOUNDS OF THIS TYPE ITS USE OR PROCEDURE FOR MANUFACTURING
JP2010513484A (en) 2006-12-20 2010-04-30 メルク・シャープ・エンド・ドーム・コーポレイション Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infections
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
NZ598927A (en) * 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DK2155758T3 (en) 2007-05-10 2012-11-05 Biocryst Pharm Inc TETRAHYDROFURO [3,4-D] DIOXOLAN COMPOUNDS FOR USE IN THE TREATMENT OF VIRUS INFECTIONS AND CANCER
CN100532388C (en) 2007-07-16 2009-08-26 郑州大学 2 '-fluoro-4' -substituted-nucleoside analogue, preparation method and application thereof
ES2614269T3 (en) 2007-08-03 2017-05-30 Biotron Limited Antiviral procedures and compositions against hepatitis C
KR101502533B1 (en) 2007-11-22 2015-03-13 에스케이케미칼주식회사 Stable pharmaceutical composition containing Taxane derivatives, and method of manufacturing the same
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
PL2280973T3 (en) * 2008-04-23 2013-05-31 Gilead Sciences Inc Carb-nucleoside analogs for antiviral therapy
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
BRPI1013643A2 (en) * 2009-02-10 2016-04-19 Gilead Sciences Inc carba-nucleoside analogues for antiviral treatment
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
WO2010108140A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
MX2011009928A (en) 2009-03-24 2012-03-16 Biocryst Pharm Inc Useful pharmaceutical salts of 7-[(3r, 4r)-3-hydroxy-4-hydroxymet hyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4 -one.
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
KR20120051022A (en) 2009-07-21 2012-05-21 길리애드 사이언시즈, 인코포레이티드 Inhibitors of flaviviridae viruses
NZ599404A (en) * 2009-09-21 2014-02-28 Gilead Sciences Inc Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
DK2480552T3 (en) 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
WO2011080568A2 (en) 2009-12-28 2011-07-07 Development Center For Biotechnology Novel pyrimidine compounds as mtor and p13k inhibitors
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (en) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PT2595980E (en) * 2010-07-22 2014-11-27 Gilead Sciences Inc METHODS AND COMPOUNDS FOR TREATING INFECTIONS BY THE PARAMYXOVIRIDAE FAMILY VIRUS
TW201305185A (en) * 2010-09-13 2013-02-01 吉李德科學股份有限公司 2'-fluoro substituted carbon-nucleoside analog for antiviral therapy
SG188223A1 (en) 2010-09-20 2013-04-30 Gilead Sciences Inc 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
LT2898885T (en) 2010-10-15 2018-02-26 Biocryst Pharmaceuticals, Inc. Pyrrolopyrimidine derivatives for use in the treatment of viral infections
ES2716158T3 (en) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleotides for the treatment of hepatitis C
TW201306841A (en) 2010-12-20 2013-02-16 Gilead Sciences Inc Methods for treating HCV
EP2697241B1 (en) 2011-04-13 2019-06-12 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
ES2639122T3 (en) 2011-05-13 2017-10-25 Zoetis Services Llc Immunogenic compositions of glycoprotein G from Hendra and Nipah virus
EP3384938A1 (en) * 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20180237T4 (en) 2011-09-16 2020-12-11 Gilead Pharmasset Llc METHODS FOR THE TREATMENT OF HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
WO2013084165A1 (en) * 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
EP2794630A4 (en) * 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
MD20140134A2 (en) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid compounds for the treatment of liver diseases
US9556216B2 (en) 2012-08-31 2017-01-31 Novartis Ag 2′-Ethynyl nucleoside derivatives for treatment of viral infections
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014042433A2 (en) * 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
MX2015005949A (en) 2012-11-16 2015-09-08 Biocryst Pharm Inc Antiviral azasugar-containing nucleosides.
JP2016501200A (en) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 2-Alkynyl-substituted nucleoside derivatives for treating viral diseases
US9243022B2 (en) * 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9283242B2 (en) 2013-01-22 2016-03-15 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US9542154B2 (en) 2013-06-25 2017-01-10 Intel Corporation Fused multiply add operations using bit masks
UA117375C2 (en) * 2013-09-04 2018-07-25 Медівір Аб Hcv polymerase inhibitors
MX377523B (en) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION.
UA119050C2 (en) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS
PE20160686A1 (en) 2014-01-30 2016-07-23 Hoffmann La Roche NEW DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
PL3114128T3 (en) 2014-03-07 2019-06-28 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN106459032B (en) 2014-05-13 2019-04-05 豪夫迈·罗氏有限公司 New dihydroquinazinones for the treatment and prevention of hepatitis B virus infection
US9616076B2 (en) * 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
JP6506836B2 (en) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel pyridazones and triazinones for the treatment and prevention of hepatitis B virus infection
TWI698444B (en) 2014-10-29 2020-07-11 美商基利科學股份有限公司 Methods for the preparation of ribosides
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107109497A (en) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 HBV cccDNA high flux new method is quantified from cell lysate by real-time PCR
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
EP3250685A1 (en) 2015-01-27 2017-12-06 F. Hoffmann-La Roche AG Recombinant hbv cccdna, the method to generate thereof and the use thereof
JP6435054B2 (en) 2015-02-11 2018-12-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Novel 2-oxo-6,7-dihydrobenzo [a] quinolidine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection
DK3349758T3 (en) 2015-09-16 2022-06-13 Gilead Sciences Inc PROCEDURES FOR THE TREATMENT OF ARENAVIRIDAE VIRUS INFECTIONS
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
BR112019016316A2 (en) 2017-02-08 2020-03-31 Biotron Limited METHODS FOR TREATING INFLUENZA
CN110869028B (en) 2017-03-14 2023-01-20 吉利德科学公司 Method of treating feline coronavirus infection
EP4219513A1 (en) 2017-05-01 2023-08-02 Gilead Sciences, Inc. Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
CN111093627B (en) 2017-07-11 2024-03-08 吉利德科学公司 Compositions containing RNA polymerase inhibitors and cyclodextrins for treating viral infections
CN111265532A (en) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 Application of substituted aminopropionate compound in treatment of 2019-nCoV infection
KR20220132608A (en) 2020-01-27 2022-09-30 길리애드 사이언시즈, 인코포레이티드 Methods for treating SARS CoV-2 infection
TWI785528B (en) * 2020-03-12 2022-12-01 美商基利科學股份有限公司 Methods of preparing 1’-cyano nucleosides

Also Published As

Publication number Publication date
MY195823A (en) 2023-02-22
BR102015027413A2 (en) 2016-05-03
PH12017500631A1 (en) 2017-09-25
EP4588928A2 (en) 2025-07-23
KR20170077167A (en) 2017-07-05
ES2674806T3 (en) 2018-07-04
JP2018172424A (en) 2018-11-08
EP3366295B1 (en) 2020-01-22
SV2017005561A (en) 2018-12-05
TWI740546B (en) 2021-09-21
PE20180202A1 (en) 2018-01-31
NZ730803A (en) 2018-09-28
IL251560A0 (en) 2017-05-29
JP2020097635A (en) 2020-06-25
AU2021201474A1 (en) 2021-03-25
PH12017500631B1 (en) 2024-01-05
AR102467A1 (en) 2017-03-01
EP3695844B1 (en) 2025-04-02
PL3366295T3 (en) 2020-08-24
US20210052613A1 (en) 2021-02-25
AU2020203892A1 (en) 2020-07-02
ES3020561T3 (en) 2025-05-23
EP3695844A1 (en) 2020-08-19
EP4588928A3 (en) 2025-09-24
HUE039231T2 (en) 2018-12-28
JP2020090536A (en) 2020-06-11
DK3366295T3 (en) 2020-04-06
ES3026734T3 (en) 2025-06-12
US9724360B2 (en) 2017-08-08
CA3184285A1 (en) 2016-05-06
KR20170066665A (en) 2017-06-14
PE20171439A1 (en) 2017-09-29
SA517381419B1 (en) 2022-07-07
JP6487547B2 (en) 2019-03-20
PL4036099T3 (en) 2025-06-23
EP4036099A1 (en) 2022-08-03
KR102694960B1 (en) 2024-08-14
BR112017007636A2 (en) 2017-12-19
EP4591935A2 (en) 2025-07-30
CL2017002693A1 (en) 2018-04-20
CU20170145A7 (en) 2018-07-05
HUE049192T2 (en) 2020-09-28
JP6220484B1 (en) 2017-10-25
ES2904298T3 (en) 2022-04-04
MX2017005252A (en) 2017-07-26
SG10202008772UA (en) 2020-10-29
SV2017005424A (en) 2018-07-18
JP7158428B2 (en) 2022-10-21
WO2016069827A1 (en) 2016-05-06
JP2022068297A (en) 2022-05-09
JP6671424B2 (en) 2020-03-25
TWI767201B (en) 2022-06-11
PH12020551055A1 (en) 2021-07-26
US20220354873A1 (en) 2022-11-10
KR20170067898A (en) 2017-06-16
PL3212174T3 (en) 2018-09-28
AU2023202679A1 (en) 2023-05-18
EP3366295A1 (en) 2018-08-29
SI3695844T1 (en) 2025-06-30
DOP2017000103A (en) 2017-05-15
MX2020012560A (en) 2021-02-09
US20190275063A1 (en) 2019-09-12
MA52506A (en) 2021-03-10
SG11201702903TA (en) 2017-05-30
CN107073005B (en) 2021-12-24
KR102453808B1 (en) 2022-10-12
MA40872A (en) 2021-05-26
SI3212175T1 (en) 2022-01-31
CA3316189A1 (en) 2026-08-05
IL251707B (en) 2019-12-31
CR20170165A (en) 2017-06-19
US10251898B2 (en) 2019-04-09
KR20240125990A (en) 2024-08-20
US20160122374A1 (en) 2016-05-05
KR20220140656A (en) 2022-10-18
AU2015339222B2 (en) 2018-11-22
TW201629076A (en) 2016-08-16
PT3366295T (en) 2020-04-21
CN114191438A (en) 2022-03-18
EP4036099B1 (en) 2025-03-19
CU20170056A7 (en) 2017-07-04
ECSP17072474A (en) 2017-12-01
EP3212175A1 (en) 2017-09-06
DK3212174T3 (en) 2018-08-06
NZ745328A (en) 2023-06-30
WO2016069825A1 (en) 2016-05-06
SG11201702904RA (en) 2017-05-30
AR102468A1 (en) 2017-03-01
EP3212174B1 (en) 2018-05-16
US20200197422A1 (en) 2020-06-25
AU2018253483A1 (en) 2018-11-15
RS57425B1 (en) 2018-09-28
JP2017186358A (en) 2017-10-12
EP4591935A3 (en) 2026-03-04
CA2963832A1 (en) 2016-05-06
KR20210152015A (en) 2021-12-14
AU2015339223A1 (en) 2017-04-27
CA2963907A1 (en) 2016-05-06
TWI687432B (en) 2020-03-11
LT3212174T (en) 2018-07-10
CN113620992B (en) 2024-09-03
EA201790630A1 (en) 2017-11-30
SI3212174T1 (en) 2018-06-29
CA2963907C (en) 2023-04-04
ECSP17025261A (en) 2017-05-31
MA40867A (en) 2017-09-06
US20180311263A1 (en) 2018-11-01
AU2021201474B2 (en) 2023-02-02
PT3212174T (en) 2018-06-28
AU2015339222A1 (en) 2017-04-27
ME03070B (en) 2019-01-20
ES2785034T3 (en) 2020-10-05
US10695357B2 (en) 2020-06-30
US11266666B2 (en) 2022-03-08
CY1120893T1 (en) 2020-05-29
EP3212175B1 (en) 2021-11-24
CN118812607A (en) 2024-10-22
CO2017003960A2 (en) 2017-07-11
EP4036099C0 (en) 2025-03-19
UA121485C2 (en) 2020-06-10
CN113549120A (en) 2021-10-26
ZA201800414B (en) 2019-10-30
JP6757294B2 (en) 2020-09-16
TWI698444B (en) 2020-07-11
SI3366295T1 (en) 2020-06-30
CN113549120B (en) 2025-04-29
US9949994B2 (en) 2018-04-24
AU2022283772A1 (en) 2023-02-02
TW202115098A (en) 2021-04-16
TW201630925A (en) 2016-09-01
JP2019048901A (en) 2019-03-28
KR101822348B1 (en) 2018-01-25
US11344565B2 (en) 2022-05-31
CR20170483A (en) 2018-01-22
KR102337664B1 (en) 2021-12-10
EA032239B1 (en) 2019-04-30
CA2963832C (en) 2020-06-16
AU2018253483B2 (en) 2020-04-16
UY36376A (en) 2016-06-01
PT3695844T (en) 2025-05-29
MX378299B (en) 2025-03-10
CN107074902A (en) 2017-08-18
MX2017005250A (en) 2017-07-26
PT3212175T (en) 2022-01-25
HK1258795A1 (en) 2019-11-22
JP2017534614A (en) 2017-11-24
NZ730809A (en) 2018-09-28
PL3212175T3 (en) 2022-02-28
US20160361330A1 (en) 2016-12-15
JP2022065066A (en) 2022-04-26
CY1122946T1 (en) 2021-10-29
CN113620992A (en) 2021-11-09
TR201809518T4 (en) 2018-07-23
LT3366295T (en) 2020-04-27
UY37464A (en) 2019-04-30
EA201790597A1 (en) 2017-11-30
IL251707A0 (en) 2017-06-29
CN107073005A (en) 2017-08-18
US20160122356A1 (en) 2016-05-05
EP3212174A1 (en) 2017-09-06
AU2019201232B2 (en) 2020-12-10
AU2019201232A1 (en) 2019-03-14
JP2017533903A (en) 2017-11-16
HRP20181130T1 (en) 2018-09-21
PL3695844T3 (en) 2025-07-21
SMT201800381T1 (en) 2018-09-13
TW202039526A (en) 2020-11-01
WO2016069826A1 (en) 2016-05-06
MD20170046A2 (en) 2017-10-31
AU2015339223B2 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
SV2017005424A (en) METHODS TO TREAT INFECTIONS BY VIRUS FILOVIRIDAE
CO2019011543A2 (en) PD-1 / PD-L1 inhibitors
CL2018001685A1 (en) Heterocyclic compounds as immuno modulators.
UY36076A (en) USEFUL COMPOUNDS AS INHIBITORS OF THE PROTEINAPROTEIN INTERACTION PD-1 / PD-L1 AND CD80 / PD-L1, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CL2018001230A1 (en) Osteoarthritis treatment
CL2017003404A1 (en) Antibacterial compounds
UY36950A (en) USEFUL COMPOUNDS AS INHIBITORS OF PROTEIN-PROTEIN INTERACTION PD-1 / PD-L1 AND CD80 / PD-L1 AND COMPOSITIONS CONTAINING THEM
CL2016003398A1 (en) Heteroaryl compounds useful as sumo activating enzyme inhibitors.
UY34750A (en) ? COMPOUNDS FOR HIV TREATMENT, COMPOSITIONS, PREPARATION METHODS, INTERMEDIARIES AND THERAPEUTIC METHODS ?.
MX2015007925A (en) NUCLEOSIDS REPLACED, NUCLEOTIDES AND ANALOGS OF THE SAME.
MX2016010216A (en) Solid pharmaceutical compositions of androgen receptor antagonists.
CL2016003277A1 (en) Methods for preparing substituted nucleotide analogs
PE20170440A1 (en) ISOINDOLINE DERIVATIVES
MX372772B (en) ARYL AND ARYLALKYL SUBSTITUTED TRICYCLIC PYRIDAZOLYL AND PYRIMIDINYL ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS.
CL2017000152A1 (en) Isoindolinone derivatives
MX2021001441A (en) A SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE.
BR112017009289A2 (en) methods of administering amantadine compositions
CL2016001623A1 (en) Benzamide and nicotinamide compounds and methods for using them.
CL2017000151A1 (en) Pyridone derivatives
AR109850A2 (en) METHODS TO TREAT INFECTIONS BY VIRUS FILOVIRIDAE
UY36086A (en) QUINOXALINE COMPOUNDS AND USES OF THE SAME